Core Viewpoint - The company, Luoxin Pharmaceutical, plans to acquire a 19.0526% stake in Beijing Luoxin Health Technology Co., Ltd. for 67.56 million yuan, increasing its ownership from 80.9474% to 100% [1] Group 1: Transaction Details - The acquisition is classified as a related party transaction since Chengdu Deyi holds more than 5% of Luoxin Pharmaceutical's shares [1] - The transaction price is based on an assessed value of 354.6 million yuan for the total equity of Beijing Health as of October 31, 2025, reflecting an increase of 538.57 million yuan [3] - The acquisition aims to optimize resource allocation and enhance operational decision-making efficiency, aligning with the company's long-term development strategy [3] Group 2: Financial Performance of Beijing Health - For the period from January to October 2025, Beijing Health reported a revenue of 63.87 million yuan, a 16.12% increase from the full-year revenue of 55.00 million yuan in 2024 [2] - The net profit for the same period was 8.18 million yuan, marking a turnaround from a loss of 15.41 million yuan in 2024 [2] - The net cash flow from operating activities was 1.98 million yuan, indicating a positive shift from negative cash flow in the previous year [2] Group 3: Company Financials and Challenges - Luoxin Pharmaceutical has faced significant losses over recent years, with net profits of -1.448 billion yuan, -639 million yuan, and -768 million yuan from 2022 to 2024, totaling approximately -2.855 billion yuan [5] - The company's revenue has declined from 6.478 billion yuan in 2021 to 2.647 billion yuan in 2024, although there was a slight recovery in 2024 [5] - The company anticipates a narrowed loss for the fiscal year 2025, projecting a net profit of between -340 million yuan and -250 million yuan [5]